Cargando…

The Pros and Cons of Cystic Fibrosis (CF) Patient Use of Herbal Supplements Containing Pulmonaria officinalis L. Extract: the Evidence from an In Vitro Study on Staphylococcus aureus CF Clinical Isolates

The justification for the use of herbal supplements with Pulmonaria officinalis L. extract (POE) in the case of staphylococcal lung colonization/infections characteristic for cystic fibrosis (CF), was examined in vitro. The impact of POE phenolic-rich fraction on the virulence attributes of CF-assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadowska, Beata, Wójcik, Urszula, Krzyżanowska-Kowalczyk, Justyna, Kowalczyk, Mariusz, Stochmal, Anna, Rywaniak, Joanna, Burzyńska, Julia, Różalska, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471470/
https://www.ncbi.nlm.nih.gov/pubmed/30909529
http://dx.doi.org/10.3390/molecules24061151
_version_ 1783412036656431104
author Sadowska, Beata
Wójcik, Urszula
Krzyżanowska-Kowalczyk, Justyna
Kowalczyk, Mariusz
Stochmal, Anna
Rywaniak, Joanna
Burzyńska, Julia
Różalska, Barbara
author_facet Sadowska, Beata
Wójcik, Urszula
Krzyżanowska-Kowalczyk, Justyna
Kowalczyk, Mariusz
Stochmal, Anna
Rywaniak, Joanna
Burzyńska, Julia
Różalska, Barbara
author_sort Sadowska, Beata
collection PubMed
description The justification for the use of herbal supplements with Pulmonaria officinalis L. extract (POE) in the case of staphylococcal lung colonization/infections characteristic for cystic fibrosis (CF), was examined in vitro. The impact of POE phenolic-rich fraction on the virulence attributes of CF-associated Staphylococcus aureus (S. aureus) clinical strains has been assessed, including pathogen adhesion, biofilm formation on native and protein-conditioned surfaces (mucin, elastin), mature biofilm eradication, staphylococcal protein A expression, α-toxin release, and S. a. adhesion to A549 cells. Cytotoxicity of the extract to lung epithelial cells was also investigated. It was found that POE has bacteriostatic effects at MIC 1–2 mg/mL, recognized as of limited efficacy, but at MIC/subMICs it targeted virulence not viability. It usually decreased S. aureus adhesion and less frequently inhibited biofilm formation on native and protein-conditioned surfaces. Observed effect seems to be related to significant reduction by POE of sortase A activity. However, in some cases POE favored the creation of biofilm by staphylococci and S. aureus adhesion to the lung epithelium was not limited. On the other side POE caused significant decrease of S. a. α-toxin synthesis and slightly weakened the expression of SpA. When used at supraMICs POE eradicated mature biofilm, but in some cases with unsatisfying outcomes. Promisingly, POE has been recognized as a safe product, with no cytotoxicity up to 4 mg/mL. These results reflect the positive, negative or neutral anti-staphylococcal properties of POE. It seems that POE may be beneficial as a prophylactic, but not as a therapeutic or supportive agent in the area of CF—integrative medicine. However, introduction the official recommendations needs further in vivo studies.
format Online
Article
Text
id pubmed-6471470
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64714702019-04-26 The Pros and Cons of Cystic Fibrosis (CF) Patient Use of Herbal Supplements Containing Pulmonaria officinalis L. Extract: the Evidence from an In Vitro Study on Staphylococcus aureus CF Clinical Isolates Sadowska, Beata Wójcik, Urszula Krzyżanowska-Kowalczyk, Justyna Kowalczyk, Mariusz Stochmal, Anna Rywaniak, Joanna Burzyńska, Julia Różalska, Barbara Molecules Article The justification for the use of herbal supplements with Pulmonaria officinalis L. extract (POE) in the case of staphylococcal lung colonization/infections characteristic for cystic fibrosis (CF), was examined in vitro. The impact of POE phenolic-rich fraction on the virulence attributes of CF-associated Staphylococcus aureus (S. aureus) clinical strains has been assessed, including pathogen adhesion, biofilm formation on native and protein-conditioned surfaces (mucin, elastin), mature biofilm eradication, staphylococcal protein A expression, α-toxin release, and S. a. adhesion to A549 cells. Cytotoxicity of the extract to lung epithelial cells was also investigated. It was found that POE has bacteriostatic effects at MIC 1–2 mg/mL, recognized as of limited efficacy, but at MIC/subMICs it targeted virulence not viability. It usually decreased S. aureus adhesion and less frequently inhibited biofilm formation on native and protein-conditioned surfaces. Observed effect seems to be related to significant reduction by POE of sortase A activity. However, in some cases POE favored the creation of biofilm by staphylococci and S. aureus adhesion to the lung epithelium was not limited. On the other side POE caused significant decrease of S. a. α-toxin synthesis and slightly weakened the expression of SpA. When used at supraMICs POE eradicated mature biofilm, but in some cases with unsatisfying outcomes. Promisingly, POE has been recognized as a safe product, with no cytotoxicity up to 4 mg/mL. These results reflect the positive, negative or neutral anti-staphylococcal properties of POE. It seems that POE may be beneficial as a prophylactic, but not as a therapeutic or supportive agent in the area of CF—integrative medicine. However, introduction the official recommendations needs further in vivo studies. MDPI 2019-03-22 /pmc/articles/PMC6471470/ /pubmed/30909529 http://dx.doi.org/10.3390/molecules24061151 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sadowska, Beata
Wójcik, Urszula
Krzyżanowska-Kowalczyk, Justyna
Kowalczyk, Mariusz
Stochmal, Anna
Rywaniak, Joanna
Burzyńska, Julia
Różalska, Barbara
The Pros and Cons of Cystic Fibrosis (CF) Patient Use of Herbal Supplements Containing Pulmonaria officinalis L. Extract: the Evidence from an In Vitro Study on Staphylococcus aureus CF Clinical Isolates
title The Pros and Cons of Cystic Fibrosis (CF) Patient Use of Herbal Supplements Containing Pulmonaria officinalis L. Extract: the Evidence from an In Vitro Study on Staphylococcus aureus CF Clinical Isolates
title_full The Pros and Cons of Cystic Fibrosis (CF) Patient Use of Herbal Supplements Containing Pulmonaria officinalis L. Extract: the Evidence from an In Vitro Study on Staphylococcus aureus CF Clinical Isolates
title_fullStr The Pros and Cons of Cystic Fibrosis (CF) Patient Use of Herbal Supplements Containing Pulmonaria officinalis L. Extract: the Evidence from an In Vitro Study on Staphylococcus aureus CF Clinical Isolates
title_full_unstemmed The Pros and Cons of Cystic Fibrosis (CF) Patient Use of Herbal Supplements Containing Pulmonaria officinalis L. Extract: the Evidence from an In Vitro Study on Staphylococcus aureus CF Clinical Isolates
title_short The Pros and Cons of Cystic Fibrosis (CF) Patient Use of Herbal Supplements Containing Pulmonaria officinalis L. Extract: the Evidence from an In Vitro Study on Staphylococcus aureus CF Clinical Isolates
title_sort pros and cons of cystic fibrosis (cf) patient use of herbal supplements containing pulmonaria officinalis l. extract: the evidence from an in vitro study on staphylococcus aureus cf clinical isolates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471470/
https://www.ncbi.nlm.nih.gov/pubmed/30909529
http://dx.doi.org/10.3390/molecules24061151
work_keys_str_mv AT sadowskabeata theprosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT wojcikurszula theprosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT krzyzanowskakowalczykjustyna theprosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT kowalczykmariusz theprosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT stochmalanna theprosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT rywaniakjoanna theprosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT burzynskajulia theprosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT rozalskabarbara theprosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT sadowskabeata prosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT wojcikurszula prosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT krzyzanowskakowalczykjustyna prosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT kowalczykmariusz prosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT stochmalanna prosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT rywaniakjoanna prosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT burzynskajulia prosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates
AT rozalskabarbara prosandconsofcysticfibrosiscfpatientuseofherbalsupplementscontainingpulmonariaofficinalislextracttheevidencefromaninvitrostudyonstaphylococcusaureuscfclinicalisolates